These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 30143249)

  • 1. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia.
    Galan A; Rousset P; Mercier F; Képénékian V; Valette PJ; Glehen O; Passot G
    Eur J Surg Oncol; 2018 Nov; 44(11):1818-1823. PubMed ID: 30143249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes.
    Robella M; Vaira M; Cinquegrana A; De Simone M
    Minerva Chir; 2019 Jun; 74(3):195-202. PubMed ID: 29589675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.
    Mercier F; Jeremie G; Alyami M; Delphine V; Vahan K; Pascal R; Sylvie I; Guillaume P; Olivier G
    Surg Endosc; 2020 Nov; 34(11):4916-4923. PubMed ID: 31792692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
    Iversen LH; Rasmussen PC; Hagemann-Madsen R; Laurberg S
    Colorectal Dis; 2013 Jul; 15(7):e365-72. PubMed ID: 23458368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
    Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
    Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 12. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei.
    Benhaim L; Faron M; Gelli M; Sourrouille I; Honoré C; Delhorme JB; Elias D; Goere D
    Surg Oncol; 2019 Jun; 29():78-83. PubMed ID: 31196498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Papageorgiou D; Manatakis DK; Papakonstantinou K; Kyriazanos ID
    Arch Gynecol Obstet; 2020 Oct; 302(4):793-799. PubMed ID: 32653946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
    BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
    Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.
    Narasimhan V; Das A; Warrier S; Lynch C; McCormick J; Tie J; Michael M; Ramsay R; Heriot A
    Langenbecks Arch Surg; 2019 Aug; 404(5):527-539. PubMed ID: 31377856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
    Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
    Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
    Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.